|
Aug 12
|
William Blair Remains Bullish on Genmab A/S (GMAB)
|
|
Aug 8
|
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
|
|
Aug 8
|
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
|
|
Aug 8
|
Epkinly breaks ground in Phase III FL trial
|
|
Aug 8
|
Genmab AS (GMAB) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements
|
|
Aug 7
|
Genmab raises full-year outlook, shares rise
|
|
Aug 7
|
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
|
|
Aug 7
|
Genmab Announces Financial Results for the First Half of 2025
|
|
Aug 7
|
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
|
|
Aug 6
|
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
|
|
Aug 5
|
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
|
|
Aug 5
|
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
|
|
Aug 4
|
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
|
|
Aug 4
|
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
|
|
Aug 4
|
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
|
|
Aug 1
|
GMAB vs. ACAD: Which Stock Is the Better Value Option?
|
|
Jul 29
|
Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More
|
|
Jul 28
|
TD Cowen Maintains a Hold on Genmab A/S (GMAB)
|
|
Jul 26
|
Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
|
|
Jul 25
|
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
|